Noni (Morinda citrifolia) is a widely plant-based herbal product with purported antioxidant, anti-inflammatory, and immunomodulatory properties and is widely available in oral, liquid, and topical formulations. Hepatotoxicity from juice and oral formulations are infrequent and liver injury associated with topical noni exposure has not previously been described. We report the case of a 60-year-old male with a history of hypertension and hypothyroidism who presented with 5 days of jaundice, generalized pruritus, dark urine, and acholic stools. Laboratory evaluation showed elevated liver enzymes in a cholestatic pattern. The patient reported prolonged use of a topical noni-containing analgesic cream for approximately 8 months, which had been discontinued 3 months prior to symptom onset. A through diagnostic evaluation excluded viral, autoimmune, and metabolic etiologies of the liver disease. Given the exposure history, clinical presentation, and exclusion of alternative diagnoses, the drug-induced liver injury was attributed to the topical noni product. The management included close outpatient follow-up until resolution of liver function tests 6 months after discharge after the discontinuation of the product. The precise mechanism for noni toxicity remains unclear, but a potential proposed pathway includes anthraquinone-mediated oxidative stress with subsequent mitochondrial dysfunction, but further investigation is warranted to better characterize systemic absorption and hepatotoxic risk associated with topical noni formulations.
Kim et al. (Wed,) studied this question.